Different cancer chemopreventive agents may act synergistically and their combination may produce enhanced protective effects against carcinogenesis than each individual agent alone. Herein, we investigated the chemopreventive effects of nobiletin (NBT, a citrus polymethoxyflavone) and atorvastatin (ATST, a lipid-lowering drug) in colon cancer cells/ macrophages and an azoxymethane (AOM)-induced colon carcinogenesis rat model. The results demonstrated that cotreatments of NBT/ATST produced enhanced growth inhibitory and anti-inflammatory effects on the colon cancer cells and macrophages, respectively. Isobologram analysis confirmed that these interactions between NBT and ATST were synergistic. NBT/ATST co-treatment also synergistically induced extensive cell cycle arrest and apoptosis in colon cancer cells. Oral administration of NBT (0.1%, w/w in diet) or ATST (0.04%, w/w in diet) significantly decreased colonic tumor incidence and multiplicity in AOM-treated rats. Most importantly, co-treatment of NBT/ATST at their half doses (0.05% NBT + 0.02% ATST, w/w in diet) resulted in even stronger inhibitory effects on colonic tumor incidence and multiplicity than did NBT or ATST alone at higher doses. Statistical analysis confirmed that the enhanced chemopreventive activities against colon carcinogenesis in rats by the NBT/ATST combination were highly synergistic. Our results further demonstrated that NBT/ ATST co-treatment profoundly modulated key cellular signaling regulators associated with inflammation, cell proliferation, cell cycle progression, apoptosis, angiogenesis and metastasis in the colon of AOM-treated rats. In conclusion, for the first time, our results demonstrated a strong synergy in inhibiting colon carcinogenesis produced by the co-treatment of NBT and ATST, which provided a scientific basis for using NBT in combination with ATST for colon cancer chemoprevention in humans.
Introduction
A growing body of evidence has suggested that combination of different cancer chemopreventive agents may produce enhanced protective effects against carcinogenesis in comparison with the effects produced by each individual agent alone. The enhanced efficacy by the combination regimen can decrease the required dosage for each single agent in the combination, which in turn may reduce the potential side effects from high-dose administration (1, 2) . As a cancer of high incidence, colon cancer has been investigated as a target of combination regimen. Accumulating studies suggest that dietary bioactive components in combination may synergistically enhance the chemopreventive effects of individual component alone against colon carcinogenesis, therefore it has been considered as a promising strategy for colon cancer chemoprevention (2) . For example, Bose et al. reported that (−)-epigallocatechin-3-gallate (EGCG) and fish oil in combination synergistically reduced the tumor occurrence and number of large tumors in Apc Min/+ mice (3). Xu et al. (4) showed that a combined treatment of curcumin and green tea catechins (mainly EGCG) resulted in a stronger effect on the inhibition of aberrant crypt foci and cell proliferation in dimethylhydrazine-treated rats.
Polymethoxyflavone is a unique group of bioactive flavonoids mainly found in the citrus fruits such as sweet oranges (Citrus sinensis) and mandarin oranges (Citrus reticulate) (5) . We and others have demonstrated a wide range of biological activities of polymethoxyflavones, such as anti-inflammatory (6) (7) (8) , anticarcinogenic (9-13) and anti-adipogenic (14) effects. In particular, nobiletin (5, 6, 7, 8 ,3′,4′-hexamethoxyflavone, NBT), one of the major polymethoxyflavones, has been shown to inhibit colon carcinogenesis in different cell culture and animal models. It was found that NBT suppressed human colon cancer cell proliferation by inducing G1 cell cycle arrest (12) , and inhibited azoxymethane (AOM)-induced colon carcinogenesis in rats through increasing apoptotic activities and decreasing prostaglandin E 2 content (9) . Recently, we demonstrated that NBT inhibited AOM/ dextran sulfate sodium-induced colitis associated colon carcinogenesis in mice (10, 13) . Together, these findings suggested that NBT had high potential as a chemopreventive agent against colon carcinogenesis.
Atorvastatin (ATST, commercially sold as Lipitor® or Torvast®) is a member of statin drugs that has been used mainly for lowering blood cholesterol and prevention of cardiovascular disease. Lipitor® has become one of the top selling statins for many years. Besides its lipid-lowering effect, observational, preclinical and clinical studies have demonstrated that ATST might help prevent colon carcinogenesis (10) . In the past decade, accumulating studies have shown that combination of ATST with different dietary or pharmaclogical agents produced enhanced anti-cancer effects against various cancers, including colon (15, 16) , lung (17, 18) and prostate cancer (19, 20) .
Our long-term goal is to develop effective stratigies for the chemoprevention of colon carcinogensis. Given the high potential of NBT and ATST as chemoprevetive agents agaisnt colon carcinogenesis, we, for the first time, investigated the chemoprevtive effects of the NBT/ATST combination in both cell cultures (colon cancer cells and macrophages) and an AOMinduced colon carcinogenesis rat model.
Materials and methods

Cell cultures and treatments
HT29 human colorectal cancer cells and RAW 264.7 macrophages were obtained from American Type Cell Collection (ATCC, Manassas, VA), and have never been passaged longer than 3 months after receipt or resuscitation. These cell lines were not authenticated as it came from national repository. HT29 cells and RAW 264.7 cells were maintained in RPMI 1640 media (Mediatech, Herndon, VA) supplemented with 5 and 10% heat-inactivated fetal bovine serum, respectively, and 100 U/ml of penicillin and 0.1 mg/ml of streptomycin at 37°C with 5% CO 2 and 95% air. Cells were kept subconfluent and media were changed every 3-4 days. All cells used in experiments were between 4 and 25 passages. Nobiletin (NBT) and atorvastatin (ATST) were purchased from Bepharm Ltd. (Shanghai, China) with purity greater than 98%. Dimethylsulfoxide (DMSO) was used as vehicle to deliver NBT and ATST to the cancer cells in culture. The final concentration of DMSO in all experiments was 0.1% v/v in cell culture media.
Cell viability assay, nitric oxide assay and analyses of synergy HT29 cells (2000 cells/well) were seeded in 96-well plates. After 24 h, cells were treated with serial concentrations of NBT, ATST and their half dose combinations in 200 μl of complete media. After 72 h, the media were replaced with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich, St. Louis, MO)-containing medium for viability test as we previously reported (21) .
RAW 264.7 cells (1.0 × 10 5 cells/well) were seeded in 96-well plates. After 24 h, cells were treated with 1 μg/ml of lipopolysaccharide (LPS) with and without the test compounds followed by the measurements of cell viability and percentage inhibition of NO production over the following 24 h. The nitrite concentration in the RAW 264.7 cell culture media was measured as an indicator of nitric oxide (NO) production by the Griess reaction (6) . The concentrations of nitrite were calculated according to a standard curve constructed with sodium nitrite as a standard as we previously reported (6) .
The analyses were based on Chou and talalay's empirical method (22) with modifications as described previously (6, 15, 23) . The combination index was used to determine additivity, antagonism and synergism between the combination treatments with NBT and ATST at different dose pairs, depending on the combination index = 1, >1, and <1, respectively. The delta method (24) was used to calculate the variance of the interaction index. Data were further analyzed by using R program software.
Flow cytometric analysis of cell cycle distribution and apoptosis HT29 (7 × 10 4 cells/well) cells were seeded in 6-well plates. After 24 h of incubation for cell attachment, cells were treated with serial concentrations of NBT, ATST and their half dose co-treatment in 2 ml of serum complete media. Media containing any floating cells were harvested and combined with adherent cells that were detached by brief trypsinization (0.25% trypsin-EDTA; Mediatech). Cell pellets were washed with 1 ml of ice-cold PBS then subject to cell cycle and apoptosis analysis as we described previously (21) .
Animals, diets, experimental procedure
The protocol for the animal experiment was approved by Institutional Animal Care (permission number 2011-0066) and Use Committee of the University of Massachusetts. To evaluate the anti-carcinogenic effects of NBT, ATST and their combination, an AOM-induced rat colon carcinogenesis model is used for this study. The male F344 rats (5 weeks of age) were obtained from Charles River Laboratories (Wilmington, MA). Upon arrival, the rats were kept in a temperature-controlled animal room (23°C), humidity (65-70%) and day/night cycle (12-h light, 12 h dark) with free access to water and a modified 20% high-fat AIN-76A diet for 1 week for acclimation. Rats were then randomly divided into four groups (30 animals each). At weeks 2 and 3, rats in all groups were given subcutaneous injections of AOM (15 mg/kg) injection twice. One week after the last AOM injection, rats were given the following diet for 40 weeks: basal AIN-76A diet for Group 1, 0.1% NBT (w/w) in basal diet for Group 2, 0.04% ATST (w/w) in basal diet for Group 3, and 0.05% NBT + 0.02% ATST (w/w) in basal diet for Group 4. Body weights, food and fluid consumption and general health status were monitored twice a week. All rats were sacrificed by CO 2 asphyxiation at 40 weeks after the dietary treatments. The colon, liver and spleen were harvested and weighed. After measurement of the length, the entire colons were cut open longitudinally, rinsed with ice-cold phosphate-buffered saline (pH 7.4) and then inspected under a dissecting microscope. Number and size of tumors in the colons were documented. The sizes of tumors were determined by the following formula: tumor volume (mm 3 
Determination of colonic levels of NBT and ATST by LC-MS
Colonic mucosa samples from the rats fed with basal AIN-76A diet (control Group 1) and basal diet containing NBT/ATST (combination group) were homogenized with 50% methanol using Bead Ruptor Homogenizer (Omni International, Kennesaw GA). Samples were then extracted with equal volume of ethyl acetate for three times. The combined ethyl acetate extracts were dried under vacuum, and then dissolved in 50% methanol for LC-MS (Model 2020, Shimadzu, Kyoto, Japan) analysis. Identification and quantification of NBT and ATST were carried out using previously published method (26) . NBT and ATST, with purity greater than 98%, were used as external standards to identify and quantify the levels of NBT and ATST in the colonic mucosa of rats.
Immunoblotting
For whole cell lysate analysis, scraped colonic mucosa was homogenized on ice for 15 s using a tissue homogenizer and then lysed in 1.5 ml of ice-cold lysis buffer, supplemented with cocktails of protease inhibitor (1:100), phosphotase inhibitor 1 (1:100) and phosphotase inhibitor 2 (1:100), on ice for 30 min, followed by centrifugation at 10 000g for 30 min at 4°C. Membrane-bound proteins were prepared by using Mem-PER™ Plus Membrane Protein Extraction Kit (Thermo Fisher Scientific, Waltham, MA) following the manufacturer's instruction. Proteins were quantified by BCA protein assay kit, and 50-100 μg of proteins were resolved by SDS-PAGE and transferred to nitrocellulose membrane. After blocking, proteins of interest were probed using different antibodies at the manufacturer's recommended concentrations and then visualized using Odyssey CLx infrared imaging system (LI-COR Biosciences, Lincoln, NE). Antibodies for vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), p21 Cip1/Waf1 , cyclin D, RhoA and β-tubulin were purchased from Santa Cruz Biotechnology (Dallas, TX). Antibodies for p-EGRF, matrix metalloproteinase (MMP)-9, cleaved-caspase 7, cleaved-caspase 3, cleavedpoly (ADP-ribose) polymerase (PARP), p53, CDK2, CDK4 and cyclin E were purchased from Cell Signaling Technology (Beverly, MA). Anti-β actin antibody was from Sigma-Aldrich (St. Louis, MO).
Real-time qRT-PCR analysis
Real-time qRT-PCR analysis was conducted as previously described (6) . The primer pairs were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA) with the following primers: interleukin (IL)-1β F: 5′-TGACAGACCCCAAAAGATTAAGG-3′, R: 5′-CTCATCT GGACAGCCCAAGTC-3′; IL-6 F: 5′-CCCACCAGGAACGAAAGTCA-3′, R: 5′-CTTGCGGAGAGAAACTTCATAGC-3′; tumor necrosis factor (TNF)-α F: 5′-ACAAGGCTGCCCCGACTAT-3′, R: 5′-CTCCTGGTATGAAGTGGCAAATC-3′; GAPDH F: 5′-ACCACAGTCCATGCCATCAC-3′, R: 5′-TCCACCACCCTG TTGCTGTA-3′ (27) . A minimum of three independent experiments were carried out, and triplicate samples were tested for each treatment. The copy number of each transcript was calculated with respect to the GAPDH copy number, using the 2 −ΔΔCt method (28) .
Immunohistochemical analysis
Formalin fixed colon tissues were processed for paraffin-embedding, sectioning and immunohistochemical analysis was conducted on the colon tissue sections as previously described (29, 30) . Antibody for cyclooxygenase-2 (COX-2) was purchased from Abcam (Cambridge, MA) and used at a 1:100 dilution. Positive signal was detected as a brown color under a light microscope. Quantification of COX-2-labeling index (%) was determined in five different fields (×150) for each rat by ImageJ (National Institutes of Health).
Statistical analysis
All data were presented as mean ± SD. Student's t-test was used to test the mean difference between two groups. Analysis of variance (ANOVA) model was used for the comparison of differences among three or more groups. A P value <0.05 was considered to be statistically significant. The interaction between NBT and ATST (synergistic, additive, or antagonistic) on cell cycle distribution and apoptosis in HT29 cells, and in the animal study was analyzed based on the "simple designs and model-free tests for synergy" by Laska et al. (31) .
Results and discussion
NBT/ATST co-treatment synergistically inhibited the growth of human colon cancer cells.
To establish the mode of interaction between NBT and ATST in inhibiting colon cancer cell growth, firstly we determined the effects of NBT, ATST and their combination on the cell proliferation of HT29 human colon cancer cells. Cells were treated with NBT (at 3, 6, 12, 24, 36 μM), ATST (at 1.5, 3, 6, 12, 18 μM), or NBT/ ATST combination (at 1.5/0.75, 3/1.5, 6/3, 12/6, 18/9 μM) for 72 h before their viability was quantified. As shown in Figure 1B , NBT and ATST treatments caused a dose-dependent growth inhibition on HT29 cells. Importantly, we observed that the combinations of NBT and ATST (at the half concentrations of NBT and ATST in the singular treatments) resulted in a much stronger growth NO production was measure by NO assay as described in Material and methods.
Data were shown as mean ± SD (n = 6).
inhibitory activities on cancer cells than the singular treatments with NBT or ATST at full doses. For example, a combination of 12 μM of NBT and 6 μM of ATST caused a 66% inhibition, while 24 μM of NBT alone and 12 μM of ATST alone only resulted in 29 and 20% inhibition, respectively. Similarly, 18 μM of NBT plus 9 μM of ATST in combination caused a 94% inhibition, while 36 μM of NBT alone and 18 μM of ATST alone only led to 43 and 39% inhibition, respectively. It is noteworthy that the growth inhibitory effect of 12 μM of NBT plus 6 μM of ATST co-treatment was also stronger than that produced by 36 μM of NBT alone or 18 μM of ATST alone.
As we observed significantly enhanced growth inhibitory effects of NBT/ATST co-treatments in comparison with the singular treatments with NBT or ATST, we further determined the mode of interaction between NBT and ATST using isobologram analysis adapted from Chou & Talalay's empirical method (22) with modifications as we described previously (6, 15, 23) . As shown in Figure 2A , the median effect plot confirmed that the linear regression model used in the isobologram analysis was wellfitted to the dose-response relationship of NBT, ATST and their combinations within the concentration ranges exploited herein. Based on the median effect plot, we calculated the interaction index of each combination dose pair of NBT/ATST as described in Materials and methods. The interaction index was calculated and used to determine additivity, synergism, or antagonism of each combination dose pair depending on interaction index =1, <1, or >1, respectively. If the interaction index is smaller than 0.3, there is a strong synergism between two tested compounds (22) . All five NBT/ATST combination dose pairs resulted in interaction indexes lower than 0.8, indicating synergistic interaction between NBT and ATST in terms of inhibiting HT29 cell proliferation. Moreover, the interaction indexes of NBT/ATST at the two highest dosed pairs (12 μM of NBT + 6 μM of ATST and 18 μM of NBT + 9 μM of ATST) were 0.18 and 0.04, respectively. Both were lower than 0.3, suggesting a strong synergism between NBT and ATST. Overall, our results demonstrated a synergistic interaction between NBT and ATST in inhibiting the growth of human colon cancer cells.
NBT and ATST synergistically inhibited LPS-induced inflammation in RAW 264.7 macrophages
Controlling inflammation has been recognized as an important approach for colon cancer chemoprevention (32) . To better understand the protective effects of NBT/ATST co-treatment against colon carcinogenesis, we utilized LPS-stimulated macrophages to determine the anti-inflammatory activity of NBT/ATST combination. As shown in Figure 1C , within the nontoxic dose ranges of NBT and ATST (cell viability ≥ 90%, data not shown), single treatment of NBT and ATST at a concentration range of 8-40 µM, led to a dose-dependent inhibition on LPS-induced nitric oxide (NO) production. Similar to the synergistic growth inhibition we observed in HT29 cells, we found that the half dose combinations of NBT and ATST at a 1:1 ratio resulted in a significantly stronger suppression of NO production in LPS-stimulated macrophages. Using isobologram analysis as described above, we confirmed that these enhanced anti-inflammatory activities by NBT/ATST combination were synergistic. As shown in Figure 2B , the median effect plot shows that the linear regression model used in the isobologram analysis well fitted the dose-response relationship of NBT, ATST and their co-treatments within the concentration ranges exploited. Based on the median effect plot, the interaction index of each combination dose pair of NBT/ ATST was calculated. We found that all five NBT/ATST combination dose pairs resulted in interaction indexes between 0.53 and 0.69, indicating synergistic interactions between NBT and ATST in terms of attenuating NO production in LPS-stimulated RAW 264.7 macrophages. These results demonstrated enhanced antiinflammatory effects by NBT/ATST combination in comparison to NBT or ATST alone, which supports the utilization of NBT/ ATST combination for chemoprevention of inflammation-associated diseases such as colon cancer.
NBT/ATST co-treatment synergistically induced G0/ G1 cell cycle arrest and cellular apoptosis in human colon cancer cells
To further investigate the mechanism of NBT/ATST co-treatment in inhibiting the growth of colon cancer cells, we determined its effect on cell cycle and apoptosis by flow cytometric analysis. Uncontrolled cell proliferation is one important characteristics of cancerous cells, thus induction of cell cycle arrest is a promising approach to regulate abnormal cell growth (33) . As shown in Figure 3A , treatments with NBT (36 μM), ATST (18 μM) and their half dose co-treatment (18 μM of NBT + 9 μM of ATST) for 24 h resulted in cell cycle arrest at G0/G1 phase in HT29 cells, and the effect of NBT/ATST co-treatment was stronger than those of NBT or ATST alone. Specifically, NBT (36 μM) and ATST (18 μM) alone increased the cell population in G0/G1 phase by 8.3 and 12.7%, respectively, compared to the control cells. However, their half dose combination increased the cell population in G0/G1 phase by 30.4%, compared to the control cells.
Evasion of apoptosis, an essential form of programed cell death, is one of the most common hallmarks of cancer. Therefore, induction of apoptosis of cancer cells is another critical strategy for cancer prevention and treatment (33) . To determine the pro-apoptotic effects of NBT/ATST combination, we performed annexin-V/propidium iodine double staining assay to evaluate the cellular apoptosis of HT29 cells caused by the combination treatment. As shown in Figure 3B , NBT at 36 μM did not caused significant change in the apoptotic cell population, in comparison to the control cells; while ATST at 18 μM significantly increased early and late apoptotic cell population by 2.5-and 2.6-fold, respectively. In contrast, the half dose NBT/ ATST co-treatment (18 μM of NBT + 9 μM of ATST) produced a much stronger induction of apoptosis than that produced by ATST or NBT at full doses alone. The co-treatment resulted in 7.9-and 4.1-fold increase in early and late apoptotic cell population compared to the control, respectively. Using the statistical method established by Laska et al. (31) , we analyzed the cell cycle and cellular apoptosis data and it was confirmed that the stronger effects produced by the NBT/ATST combination were synergistic.
Overall, our results showed that combination treatment with NBT and ATST at half doses produced more potent effects in inducing G0/G1 cell cycle arrest and cellular apoptosis in human colon cancer cells than NBT or ATST at full dose alone. This suggested that combined treatments with NBT and ATST produced synergy in inducing cell cycle arrest and cellular apoptosis in human colon cancer cells (Figure 3) , which may contribute to the synergism observed between NBT and ATST in inhibiting cell proliferation of the cancer cells ( Figure 1B ) These exciting findings on the synergistic anti-cancer effects of NBT and ATST on cancer cells provided a solid basis to conduct in vivo studies to validate these effects in animal models.
Oral administration of NBT/ATST in combination synergistically suppressed colon carcinogenesis in AOM-treated rats
The AOM-induced rat colon carcinogenesis model is a wellestablished and widely used model for human colon carcinogenesis (34) , by which many cancer chemopreventive agents have been identified. This model shares many molecular events of pathogenesis with the human situation (35) . Next, we utilized the AOM-treated rat model to determine chemopreventive effects of NBT (0.1% in diet), ATST (0.04% in diet) and their half dose combination (0.05% NBT + 0.02% ATST in diet) against colon carcinogenesis. Body weight and food intake of rats were monitored twice a week as important indicators of potential toxicity of NBT, ATST and their combination. No significant difference was observed among four groups of rats in body weight and food intake during the entire experimental period (final body weights were shown in the Table 1 ). There was no significant difference in the weight of liver and spleen among control, NBT and NBT/ATST co-treatment groups, while ATST resulted in a slight decrease in the liver weight in comparison with the control group. No apparent behavioral or appearance difference was observed among four groups either. These results indicated there was no noticeable side effect caused by oral administration of NBT, ATST or their half dose combination at the doses tested. The ratio of colon weight/length reflects the severity of colitis, and thus is often considered as an important marker of inflammation in the colon in animal models (36) . Dietary NBT showed a trend in decreasing the colon weight/length ratio by 10%, but it was not statistically significant (P = 0.075). ATST treatment decreased the ratio by 18.4%, while the half dose combination of NBT and ATST reduced the ratio by 15.3%. There is no statistical difference between ATST treatment and the combination treatment.
AOM injection resulted in tumor incidence of 80.0% and tumor multiplicity of 1.86 ± 0.35 colonic tumors per rat in the control group. Dietary administration of 0.1% NBT significantly decreased tumor incidence to 66.7% and tumor multiplicity to 1.19 ± 0.21 tumors per rat; and 0.04% ATST decreased tumor incidence to 60.0% and tumor multiplicity to 1.10 ± 0.23. The cotreatment with 0.05% NBT and 0.02% ATST produced superior anti-tumor effects by reducing tumor incidence to 50.0% and tumor multiplicity to 0.62 ± 0.18 tumors per rat. This indicated that NBT/ATST at half dose combination led to a 37.5% reduction in tumor incidence and 66.7% in tumor multiplicity compared to the control rats. It is noteworthy that the inhibitory effects of the half dose combination of NBT and ATST on colon carcinogenesis were significantly stronger than those produced by NBT or ATST alone at the full doses. These findings demonstrated that combination of NBT and ATST produced enhanced chemopreventive effects against colon carcinogenesis in AOM-treated rats.
Using the statistical method established by Laska et al. (31) , the tumor incidence and tumor multiplicity data were analyzed and the results showed that the enhanced chemopreventive effects by the combination treatment were synergistic. The dose of NBT used in the combination was based on the previous studies that showed NBT inhibited colon carcinogenesis in different rodent models (10) . This dose is equivalent to approximately 100 mg/day for human oral comsumption, which is a reasonably achievable in humans. On the other hand, the dose of ATST used in the combination is equivalent to about 40 mg/day for human, which is within the suggested adult dose for cholesterol reduction and cardiovascular disease prevention by ATST. In 2016, the U.S. Preventive Services Task Force released preventive medication guidelines that suggest certain elderly adults can start taking low-dose aspirin daily to prevent cardiovascular disease and colon cancer (37) . A previous report suggested that ATST resulted in a stronger inhibition on colonic tumors than aspirin in AOM-treated rats (38) . Overall, our results provided a strong rationale to utilize ATST in combination with NBT for colonn cancer chemoprevention.
Using the LC-MS-based analysis, we determined the levels of NBT and ATST in the colonic mucosa of the rats fed with 0.05% NBT + 0.02% ATST (w/w) in the diet. The concentrations of NBT and ATST in the rat colonic mucosa were 0.70 ± 0.25 and 1.45 ± 0.49 nmol/g of tissue, respectively. If it is assumed that 1 gram of tissue gives 1 mL of volume, the aforementioned concentrations of NBT and ATST in the colonic mucosa were equivalent to 0.70 ± 0.25 and 1.45 ± 0.49 µM, respectively. These tissue concentrations were lower than the concentrations of NBT and ATST that we used in the cell culture studies. However, it is noteworthy that these colonic concentrations of NBT and ATST in the rats were achieved by an ad libitum dietary intake of NBT and ATST by the rats throughout a 40-week of feeding period. It could be speculated that a long-term in vivo tissue exposure at the relatively lower concentrations might result in similar biological effects caused by a short-term in vitro cellular exposure at the higher concentrations. This notion was supported by our results showing that an in vivo dietary NBT/ATST treatment led to a synergistic inhibition of colon carcinogenesis in rats, while an in vitro NBT/ATST co-treatment resulted to a synergistic inhibition of colon cancer cell growth in culture. To further substantiate this notion, in the following sections, we determined the molecular events caused by the dietary NBT/ATST treatment pertinent to its inhibitory effects on colonic tumors in rats.
NBT/ATST co-treatment modulated the expression of key proteins associated with cell cycle progression and apoptosis in the colon of AOM-treated rats
Our results demonstrated that NBT/ATST co-treatment inhibited the growth of human colon cancer cells by inducing cell cycle arrest and cellular apoptosis (Figure 3) . To verify if modulating cell cycle progression and apoptosis was important molecular mechanism by which the NBT/ATST co-treatment inhibited colon carcinogenesis in AOM-treated rats, we analyzed the treatment effects on key signaling proteins related with cell cycle (p21, CDK2, CDK4, cyclin D and cyclin E) and apoptosis (p53, cleaved caspase-7, cleaved caspase-3 and cleaved PARP) in the colonic mucosa of the AOM-treated rats by immunoblotting. Cell cycle progression is precisely regulated by checkpoints and different CDK complexes. p21 is an important CDK inhibitor that mainly functions as a regulator of cycle cycle at G1 and S phase (33, 39) . The activation of CDK4-cyclin D and CDK6-cyclin D complexes is essential for the transition from early to mid G1 phase, whereas the CDK2-cyclin E complex is necessary for the transition from mid G1 to S phase (40). As shown in Figure 4A , compared to the control group, all treatment groups significantly induced the expression levels of p21 and reduced the expression levels of CDK2, CDK4, cyclin D and cyclin E. Overall, NBT, ATST and their half dose combination produced similar effects on the aforementioned proteins, except for cyclin D where combination treatment showed stronger effects than NBT or ATST alone. These results confirmed that NBT, ATST and their combination modulated key proteins regulating cell cycle progression in such a way that cell cycle proliferation was likely inhibited in the colonic tissue of AOM-treated rats. Cleavage of caspase-7 and its downstream effector caspase-3 plays critical roles in triggering cellular apoptosis. Cleavage of caspase-3 can further cause the cleavage of PARP, which can ultimately lead to apoptosis by interfering chromatin condensation and DNA fragmentation (41) . As shown in Figure 4A , NBT/ATST co-treatment increased the expression levels of tumor suppressor p53, as well as cleavage of caspase-7, caspase-3 and PARP in the colonic tissue of AOM-treated rats, indicating enhanced level of cellular apoptosis. The results also showed that the combined NBT/ATST treatment had stronger effects in increasing the levels of p53, cleaved caspase-3 and cleaved PARP in comparison with that of NBT or ATST alone, suggesting potential synergistic interaction between NBT and ATST. These results were consistent with those in the cell culture study ( Figure 3B ).
NBT/ATST co-treatment reduced the mRNA levels of pro-inflammatory cytokines and protein level of COX-2 in the colon of AOM-treated rats Numerous studies have demonstrated that colonic inflammation such as that occurred in inflammatory bowel diseases could significantly increase the risk of colon cancer (42) . Pro-inflammatory cytokines, such as IL-1β, IL-6 and TNF-α play crucial roles in the pathogenesis of inflammatory bowel diseases, where they regulate various aspects of inflammatory responses (43) . Blockade of IL-1β and TNF-α activity was shown to reduce tumor growth in rodent colon cancer models. Additionaly, suppression of IL-1β activity was found to inhibit colon carcinogenesis in mice by interfering macrophage-dependent IL-6 secretion (43). We previously reported that NBT showed significant inhibition on AOM/dextran sulfate sodium-induced improper upregulation of IL-1β, IL-6 and TNF-α in mice (10) . ATST is also reported to exert anti-inflammatory effects by modulating key inflammatory biomarkers, such as inducible nitric oxide synthase (iNOS), COX-2, phospho-p65, IL-1β, IL-4 and TNF-α in AOM-treated rats (44) . Our in vitro data showed that NBT/ATST co-treatments can attenuate LPS-stimulated overproduction of NO in macrophages, suggesting a synergistic anti-inflammatory potency of this combination ( Figure 1C) . Therefore, we next evaluated the anti-inflammatory effects of NBT, ATST and their half dose combination in the colon of AOM-treated rats by real-time qRT-PCR analysis. As shown in Figure 5 , NBT, ATST and their half dose combination led to significant decreases in the mRNA levels of IL-1β by 84, 92 and 93% compared to the control group, respectively. For IL-6, NBT, ATST and their combination reduced its mRNA level by 66, 77 and 84%, respectively. Moreover, NBT, ATST and their combination also reduced the mRNA level of TNF-α by 62, 79 and 85%, respectively. It is noteworthy that the aforementioned inhibitory effects of NBT/ATST combination were stronger than those produced by NBT or ATST alone at higher doses.
In tumor cells and inflammatory cells, transcription factor nuclear factor-kappa B (NF-κB) contributes to the activation of genes coding pro-inflammatory enzymes, such as COX-2, which in turn leads to the overproduction of prostaglandins such as PGE 2 , a key inflammatory mediator that promotes tumor growth and metastasis. Therefore, we determined the effects of the NBT/ATST combination on COX-2 expression in rat colon by immunohistochemical analysis. As shown in Figure 5B and C, compared with the control, NBT or ATST treatment alone moderately decreased the expression level of COX-2 in the colonic tissues (NBT's effect was not statistically significant). However, half dose NBT/ATST co-treatment resulted in a much stronger reduction on the COX-2 expression in comparison with these produced by NBT or ATST alone at the higher doses. These results indicated that NBT/ATST co-treatment showed stronger inhibitory effects on inflammatory responses in the colon of AOM-treated rats than those produced by NBT or ATST at higher doses alone, suggesting that the enhanced chemopreventive effects of the NBT/ATST combination were assocaited its superior anti-inflammatory properties than NBT or ATST alone.
NBT/ATST co-treatment reduced the protein levels of VEGF and MMP-9 in the colon of AOM-treated rats Progression stage of carcinogenesis involves unlimited replication of tumor cells, activation of angiogenesis (new blood vessel formation), beginning of tissue invasion and metastasis growth (45) . Therefore, angiogenesis and metastasis have been recognized as important targets for cancer chemoprevention. Our results clearly showed that half dose NBT/ATST co-treatment resulted in drastic decreases in the colonic levels of VEGF and MMP-9 compared to the control group ( Figure 4A ), and these effects were either stronger than or similar to those produced by individual treatment with NBT or ATST at the full doses. VEGF is one of the major growth factors that activate endothelial cell functions during angiogenesis. VEGF is often found to be overexpressed in many tumors (46) . Migration and invasion of tumor cells are important events during metastasis process of carcinogenesis. Proteolysis enzymes MMPs plays important roles in the disruption of extracellular matrix.
Among MMP family, MMP-9 is a main proteolysis enzyme that breaks down extracellular matrix structure and thus opens paths for tumor cell migration and metastasis (47, 48) . Together, our results suggested that NBT/ATST co-treatment had the potential of suppressing the angiogenesis and metastasis of colon cancer.
NBT/ATST co-treatment decreased the expression levels of membrane-bound p-EGFR, EGFR and RhoA in the colon of AOM-treated rats
We next investigate the effects of NBT, ATST and their half dose combination on the expression levels of membrane-bound phosphorylated-EGFR (p-EGFR), EGFR and RhoA in the colon of AOM-treated rats. As shown in Figure 4B , NBT modestly decreased the levels of p-EGFR and RhoA compared to the control, whereas ATST treatment significantly reduced the levels of p-EGFR, EGFR and RhoA. More importantly, the half dose combination of NBT and ATST markedly reduced the protein levels of p-EGFR, EGFR and RhoA, and these effects were stronger than those of NBT or ATST alone at the higher doses. For example, for RhoA, NBT and ATST alone caused 1.2-and 2.1-fold decrease, respectively, while the co-treatment led to a 4.5-fold decrease compared to the control.
Mevalonate, a major product of HMG-CoA reductase activity, is the precursor for some intermediate lipid products such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate. These lipid products isoprenylate various small GTPase proteins such as the Ras/Rho superfamily. The isoprenylation is necessary for cytosol-to-membrane translocation of these small GTPase proteins and thus become functional (49, 50) . Ras homolog gene family, member A (RhoA) is a major member of Ras/Rho superfamily that has been proven to be involved in cellular adhesion, migration, metastasis, proliferation and apoptosis of cancer cells, and is correlated with poor prognosis in multiple cancers, including colon, breast, pancreas and bladder cancer (51) (52) (53) . Previous studies have indicated that statins can suppress the geranylgeranylation of RhoA and in turn inhibit epidermal growth factor-induced invasion of cancer cells (53) . In vitro study on human colon cancer cells showed that ATST modulated HMG-CoA reductase and geranylgeranylation of RhoA (54) . EGFR is a transmembrane glycoprotein that belongs to the family of HER receptors. Activation of EGFR initiates intracellular signaling pathways that lead to increased cell proliferation and various processes associated with cell survival. The expression of p-EGFR was detected in about 40% of stage I and II colon carcinomas. Overexpression of p-EGFR and EGFR are closely related with tumor cell hyperproliferation (55). Our results indicated that NBT/ATST co-treatment significantly decreased the protein levels of membrane-bound p-EGFR, EGFR and RhoA, suggesting that the chemopreventive effects of the NBT/ATST combination could be at least partially attributed to its ability to inhibit EGFR activation and RhoA-mediated signaling pathways.
In conclusion, for the first time, our results demonstrated that NBT and ATST produced a strong synergistic interaction in inhibiting colon carcinogenesis in both human cancer cells and AOM-treated rats. The enhanced anti-cancer effects by the combination treatment were associated with inhibition of cell cycle progression, induction of cellular apoptosis, as well as inhibition of pro-inflammatory cytokines. The fact that combination of NBT and ATST at their half doses produced stronger anti-cancer effects than NBT or ATST alone at their full doses provided a strong basis to utilize NBT/ATST combination for colon cancer chemoprevention.
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